Interventional Cardiology. Группа авторов

failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013; 128(16):1810–52.

      79 79 Cosyns B, Plein S, Nihoyanopoulos P, et al. European Association of Cardiovascular Imaging (EACVI) position paper: Multimodality imaging in pericardial disease. Eur Heart J Cardiovasc Imaging. 2015; 16(1):12–31.

      80 80 Partington SL, Valente AM. Cardiac magnetic resonance in adults with congenital heart disease. Methodist Debakey Cardiovasc J. 2013; 9(3):156–62.

      81 81 Hundley WG, Li HF, Lange RA, et al. Assessment of left‐to‐right intracardiac shunting by velocity‐encoded, phase‐difference magnetic resonance imaging. A comparison with oximetric and indicator dilution techniques. Circulation. 1995; 91(12):2955–60.

      82 82 Beerbaum P, Körperich H, Barth P, et al. Noninvasive quantification of left‐to‐right shunt in pediatric patients: phase‐contrast cine magnetic resonance imaging compared with invasive oximetry. Circulation. 2001; 103(20):2476–82.

      83 83 Prakash A, Powell AJ, Geva T. Multimodality noninvasive imaging for assessment of congenital heart disease. Circ Cardiovasc Imaging. 2010; 3(1):112–25.

      84 84 Carminati M, Agnifili M, Arcidiacono C, et al. Role of imaging in interventions on structural heart disease. Expert Rev Cardiovasc Ther. 2013; 11(12):1659–76.

      85 85 Eicken A, Ewert P, Hager A, et al. Percutaneous pulmonary valve implantation: two‐centre experience with more than 100 patients. Eur Heart J. 2011; 32(10):1260–5.

      86 86 Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the u.s. Clinical trial. J Am Coll Cardiol. 2009; 54(18):1722–9.

      87 87 Suzuki J, Caputo GR, Kondo C, Higgins CB. Cine MR imaging of valvular heart disease: display and imaging parameters affect the size of the signal void caused by valvular regurgitation. AJR Am J Roentgenol. 1990; 155(4):723–7.

      88 88 Mathew RC, Löffler AI, Salerno M. Role of Cardiac Magnetic Resonance Imaging in Valvular Heart Disease: Diagnosis, Assessment, and Management. Curr Cardiol Rep. 2018; 20(11):119.

      89 89 Kilner PJ, Manzara CC, Mohiaddin RH, et al. Magnetic resonance jet velocity mapping in mitral and aortic valve stenosis. Circulation. 1993; 87(4):1239–48.

      90 90 Loubeyre P, Delignette A, Bonefoy L, et al. Magnetic resonance imaging evaluation of the ascending aorta after graft‐inclusion surgery: comparison between an ultrafast contrast‐enhanced MR sequence and conventional cine‐MRI. J Magn Reson Imaging. 1996; 6(3):478–83.

      91 91 Fattori R, Nienaber CA. MRI of acute and chronic aortic pathology: pre‐operative and postoperative evaluation. J Magn Reson Imaging. 1999; 10(5):741–50.

      92 92 Nielsen JC, Powell AJ, Gauvreau K, et al. Magnetic resonance imaging predictors of coarctation severity. Circulation. 2005; 111(5):622–8.

      93 93 Didier D, Saint‐Martin C, Lapierre C, et al. Coarctation of the aorta: pre and postoperative evaluation with MRI and MR angiography; correlation with echocardiography and surgery. Int J Cardiovasc Imaging. 2006; 22(3–4):457–75.

      94 94 Muzzarelli S, Meadows AK, Ordovas KG, et al. Usefulness of cardiovascular magnetic resonance imaging to predict the need for intervention in patients with coarctation of the aorta. Am J Cardiol. 2012; 109(6):861–5.

      95 95 Takahashi EA, Kinsman KA, Neidert NB, Young PM. Guiding peripheral arterial disease management with magnetic resonance imaging. VASA. 2019; 48(3):217–22.

      96 96 Nael K, Villablanca JP, Saleh R, et al. Contrast‐enhanced MR angiography at 3T in the evaluation of intracranial aneurysms: a comparison with time‐of‐flight MR angiography. AJNR Am J Neuroradiol. 2006; 27(10):2118–21.

      97 97 Villablanca JP, Nael K, Habibi R, et al. 3 T contrast‐enhanced magnetic resonance angiography for evaluation of the intracranial arteries: comparison with time‐of‐flight magnetic resonance angiography and multislice computed tomography angiography. Invest Radiol. 2006; 41(11):799–805.

      98 98 Nael K, Villablanca JP, Pope WB, et al. Supraaortic arteries: contrast‐enhanced MR angiography at 3.0 T‐‐highly accelerated parallel acquisition for improved spatial resolution over an extended field of view. Radiology. 2007; 242(2):600–9.

      99 99 Fabrega‐Foster KE, Agarwal S, Rastegar N, et al. Efficacy and safety of gadobutrol‐enhanced MRA of the renal arteries: Results from GRAMS (Gadobutrol‐enhanced renal artery MRA study), a prospective, intraindividual multicenter phase 3 blinded study. J Magn Reson Imaging. 2018; 47(2):572–81.

      100 100 Holmes DR, Jr., Mack MJ, Kaul S, et al. 2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012; 59(13):1200–54.

      101 101 Jabbour A, Ismail TF, Moat N, et al. Multimodality imaging in transcatheter aortic valve implantation and post‐procedural aortic regurgitation: comparison among cardiovascular magnetic resonance, cardiac computed tomography, and echocardiography. J Am Coll Cardiol. 2011; 58(21):2165–73.

      102 102 Koos R, Altiok E, Mahnken AH, et al. Evaluation of aortic root for definition of prosthesis size by magnetic resonance imaging and cardiac computed tomography: implications for transcatheter aortic valve implantation. Int J Cardiol. 2012; 158(3):353–8.

      103 103 Ruile P, Blanke P, Krauss T, et al. Pre‐procedural assessment of aortic annulus dimensions for transcatheter aortic valve replacement: comparison of a non‐contrast 3D MRA protocol with contrast‐enhanced cardiac dual‐source CT angiography. Eur Heart J Cardiovasc Imaging. 2016; 17(4):458–66.

      104 104 Miyazaki M, Lee VS Nonenhanced MR angiography. Radiology. 2008; 248(1):20–43.

      105 105 Cavalcante JL, Schoenhagen P. Role of cross‐sectional imaging for structural heart disease interventions. Cardiol Clin. 2013; 31(3):467–78.

      106 106 Corrigan FE, 3rd, Gleason PT, Condado JF, et al. Imaging for Predicting, Detecting, and Managing Complications After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Imaging. 2019; 12(5):904–20.

      107 107 Altiok E, Frick M, Meyer CG, et al. Comparison of two‐ and three‐dimensional transthoracic echocardiography to cardiac magnetic resonance imaging for assessment of paravalvular regurgitation after transcatheter aortic valve implantation. Am J Cardiol. 2014; 113(11):1859–66.

      108 108 Ribeiro HB, Orwat S, Hayek SS, et al. Cardiovascular Magnetic Resonance to Evaluate Aortic Regurgitation After Transcatheter Aortic Valve Replacement. J Am Coll Cardiol. 2016; 68(6):577–85.

      109 109 Rogers T, Lederman RJ. Interventional CMR: Clinical applications and future directions. Curr Cardiol Rep. 2015; 17(5):31.

SECTION III Revascularization in Different Clinical Settings

      CHAPTER 11

      Stable Coronary Artery Disease

       Abhiram Prasad and Bernard J. Gersh

The main objectives of treatment for stable coronary artery disease (CAD) are the relief of symptoms related to myocardial ischemia and improvement in prognosis. Significant progress has been made over the past four decades in drug therapy, percutaneous coronary intervention (PCI), and coronary artery bypasses grafting (CABG). While this chapter focuses on percutaneous revascularization, it is important to remember that medical therapy and secondary prevention have a central role in the management of coronary atherosclerosis. Secondary prevention via lifestyle modification, treatment of conventional risk factors (Table 11.1), and drug therapy (Figure 11.1) [1–3] reduces cardiovascular mortality, myocardial infarction, unstable angina, onset of heart failure, and the need for revascularization,